A promising pipeline

Take a closer look at the progress of our first-in-class therapeutics.

	Drug	Indication*	Phase I	Phase II	Phase III	FDA Approved	Commercialization Rights† (ex-Japan and S. Korea)‡
	Difelikefalin injection	Pruritus CKD-HD§	Commercial Rights: US-Vifor EU / Other-VFMCRP||					US-Vifor EU / Other-VFMCRP||
	Oral difelikefalin	Pruritus AD	Commercial Rights: Cara					Cara
	Oral difelikefalin	Pruritus NDD-CKD	Commercial Rights: Cara					Cara
	Oral difelikefalin	Pruritus PBC	Commercial Rights: Cara					Cara
	Oral difelikefalin	Pruritus NP	Commercial Rights: Cara					Cara

1. *Cara Therapeutics has investigated difelikefalin for post-operative pain.
2. ^†Vifor has commercial rights in Non-US Fresenius Medical Care dialysis clinics under a profit-share arrangement.
3. ^‡Commercialization rights to difelikefalin in defined indications—Japan: Maruishi Pharma; South Korea: CKD Pharma.
4. ^§Approved for USA.
5. ^||VFMCRP and Cara have rights to promote in Fresenius clinics in the US under a profit-share agreement.
6. CKD-HD: Chronic Kidney Disease-Hemodialysis; NDD—CKD: Non-Dialysis Dependent-Chronic Kidney Disease; AD: Atopic Dermatitis; PBC: Primary Biliary Cholangitis; NP: Notalgia Paresthetica.